<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported) June 13, 1997
-------------
BOSTON LIFE SCIENCES, INC.
--------------------------
(Exact name of registrant as specified in its charter)
<TABLE>
<CAPTION>
<S> <C> <C>
Delaware 0-6533 87-0277826
- ------------------------------------------ ------ ------------------------------------
(State or other jurisdiction of (Commission (I.R.S. Employer Identification No.)
incorporation or organization) File No.)
31 Newbury Street, Suite 300
Boston, Massachusetts 02116
- ------------------------------------------ ------------------------------------
(Address of principal executive offices) Zip Code
</TABLE>
Registrant's telephone number, including area code (617) 425-0200
---------------
<PAGE>
Item 5. Other Events.
-------------
On June 13, 1997, Boston Life Sciences, Inc. announced that the U.S. Patent and
Trademark Office had issued notices of allowance for several claims within two
separate patent applications which had previously been licensed to BLSI by
Children's Hospital of Boston, MA. The allowed claims within these patents
cover the use of Troponin I to treat angiogenic conditions, and the composition
of its licensed Central Nervous System (CNS) growth factor.
BLSI is engaged in the research and development of novel treatments for cancer,
autoimmune diseases, and central nervous system disorders.
Item 7. Exhibits.
--------
The following Exhibits are filed as part of this report on Form 8-K:
99.1 Press Release, dated June 13, 1997.
<PAGE>
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto authorized.
BOSTON LIFE SCIENCES, INC.
Dated: June 18, 1997 By:/s/ Joseph Hernon
------------------
Joseph Hernon
Chief Financial Officer
<PAGE>
BOSTON LIFE SCIENCES, INC.
CURRENT REPORT ON FORM 8-K
EXHIBIT INDEX
Exhibit No. Page
- ----------- ----
99.1 Press Release, dated June 13, 1997 5
<PAGE>
Exhibit 99.1
FOR IMMEDIATE RELEASE
BOSTON LIFE SCIENCES ANNOUNCES NOTICE OF PATENT ALLOWANCES IN ITS CENTRAL
NERVOUS SYSTEM REGENERATION AND ANTI-ANGIOGENESIS TECHNOLOGIES
BOSTON, MA - JUNE 13, 1997 -- BOSTON LIFE SCIENCES, INC. (NASDAQ: BLSID)
announced today that the U.S. Patent and Trademark Office had issued notices of
allowance for several claims within two separate patent applications which had
previously been licensed to BLSI by Children's Hospital of Boston, MA. The
allowed claims within these patents cover the use of Troponin I to treat
angiogenic conditions, and the composition of its licensed Central Nervous
System (CNS) growth factor.
"We are extremely pleased that a Notice of Allowance on the Axogenesis Factor 1
patent has been issued, since we believe that this CNS growth factor is
particularly unique in its ability to promote axon growth in the CNS", said Marc
E. Lanser, M.D., Chief Scientific Officer of BLSI. "We view the impending
issuance of this patent as an important event in support of what we believe is
our significant proprietary position in the field of CNS regeneration to use
this unique CNS growth factor for the treatment of stroke and spinal cord
injuries."
"Given our ongoing significant effort on anti-angiogenesis as an exciting
approach to the treatment of tumor metastases, we are delighted to have received
notice of allowance of the claims related to the use of Troponin to treat
angiogenic diseases," stated David Hillson, President and CEO of BLSI. "This
notice clearly increases our confidence in continuing to develop this
potentially important anti-cancer therapeutic, although any product development
process is acknowledged to be lengthy and uncertain," added Mr. Hillson.
BLSI is engaged in the research and development of novel therapeutics for
cancer, autoimmune disease, and central nervous system disorders. BLSI's
products in clinical trials or in pre-clinical development include the above
mentioned Altropane; Troponin I, an anti-angiogenesis factor for the treatment
of solid tumors; Axogenesis Factor 1 (AF-1), a novel central nervous system
growth factor; THERAFECTIN for the treatment of Rheumatoid Arthritis; and
transcription factors to control the expression of molecules associated with
autoimmune disease and allergies.
